Skip to content

Neogen NEOG Total Liabilities

Total Liabilities at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$1.83B+3.6%
Zoetis logo
ZoetisZTS
$11.92B+26.2%
Revvity logo
RevvityRVTY
$4.81B+1.9%
Agilent Technologies logo
Agilent TechnologiesA
$5.94B-1.3%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$2.94B+3.2%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$2B+86.4%
Enterprise value$2.63B+41.6%
P/S2.3×+1.1×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Reported directly by Neogen in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Neogen’s 10-Q, filed April 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neogen's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neogen's total liabilities?
Neogen (NEOG) reported total liabilities of $1.26B in Q4 2025.
How has Neogen's total liabilities changed year-over-year?
Neogen's total liabilities decreased by 8.7% year-over-year, from $1.38B to $1.26B.
What is the long-term trend for Neogen's total liabilities?
Over 4 years (2021 to 2025), Neogen's total liabilities has grown at a 103.6% compound annual growth rate (CAGR), from $79.82M to $1.37B.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.